Jazz Pharmaceuticals plc

-1.08 (-0.71%)
Products, Regulatory

Pharma Mar Signs Agreement With Jazz Pharmaceuticals To Commercialize Lurbinectedin In Canada

Published: 10/15/2020 06:50 GMT
Jazz Pharmaceuticals PLC (JAZZ) - Signs an Agreement With Jazz Pharmaceuticals to Commercialize Lurbinectedin in Canada.
Is Eligible Under the Amended Agreement to Receive Up to US $5 Million Between an Upfront Payment and Regulatory Milestone Payments in Canada.
Also Eligible to Receive Incremental Tiered Royalties on Future Net Sales of Lurbinectedin in Canada, Ranging From High Teens Up to 30%, in Addition to Up to US $3 Million As Potential Sales Milestone Payments.
Retains Production Rights for Lurbinectedin and Will Supply the Product to Jazz.